AAN 2024 | HEP2: seizure frequency decreases over time in patients with treatment-resistant epilepsy

Jacqueline French, MD, NYU Comprehensive Epilepsy Center, New York, NY, discusses the Human Epilepsy Project 2 (HEP2) study, a multi-center study examining longitudinal seizure patterns in patients with treatment-resistant focal epilepsy. The study indicates a decline in seizure frequency over time, yet it remains uncertain whether this translates to improved quality of life (QoL). Prof. French emphasizes that therapies previously considered disease-modifying due to reduced seizure activity may not actually alter the course of the disease. To ascertain which drugs are genuinely disease-modifying, they must be compared to a control group. This interview took place at the American Academy of Neurology (AAN) Annual Meeting 2024 in Denver, CO.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.